Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Imaging Studies II: Positron Emission Tomography and Scintigraphy

Imaging Studies II: Positron Emission Tomography and Scintigraphy

Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET

Positron Emission Tomography

Positron Emission Tomography

Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...

Radiological Investigation III: Pulmonary Angiogram and PET Scan

Radiological Investigation III: Pulmonary Angiogram and PET Scan

Radiological investigations are paramount in the diagnosis and management of various pulmonary diseases. Two essential investigations are the Pulmonary Angiogram and the Positron Emission Tomography (PET) Scan.
Pulmonary Angiogram
A Pulmonary Angiogram is an invasive procedure involving injecting a contrast medium through a catheter threaded into the pulmonary artery or the right side of the heart to visualize the pulmonary vasculature. Computed Tomography (CT) scans have mainly replaced this...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Liquid biopsy for early cancer detection in hereditary cancer syndromes: current evidence.

Critical reviews in oncology/hematology·2026

Same author

Epigenetic Dysregulation of Somatostatin Receptors (SSTR) 1-5 and Therapeutic Implications in Neuroendocrine and Non-Neuroendocrine Malignancies.

International journal of cancer·2026

Same author

Effects of androgen receptor signaling inhibitors on absorbed doses in mCRPC patients undergoing [<sup>177</sup>Lu]Lu-PSMA-617 or [<sup>177</sup>Lu]Lu-PSMA-I&T therapy: dosimetry results.

European journal of nuclear medicine and molecular imaging·2026

Same author

Variant-Specific Landscape of Mutual Exclusivity Among BRAF, EGFR, and KRAS Oncogenes Reveals Overlap With Functionally Antagonistic Mutant Pairs.

International journal of cancer·2026

Same author

Spatial dissection of ADC/RPT targets defines heterogeneous expression landscapes and therapeutic implications in rhabdoid tumors.

Neuro-oncology·2026

Same author

Mutant IDH1 blocks neutropoiesis by repressing myeloid progenitor programs.

Blood·2026

Search research articles

Related Experiment Video

Updated: Jun 21, 2025

Murine Lymphocyte Labeling by 64Cu-Antibody Receptor Targeting for In Vivo Cell Trafficking by PET/CT

Murine Lymphocyte Labeling by 64Cu-Antibody Receptor Targeting for In Vivo Cell Trafficking by PET/CT

Published on: April 29, 2017

New PET Tracers for Lymphoma.

Johanna S Enke¹, Ralph A Bundschuh¹, Rainer Claus²

¹Nuclear Medicine, Faculty of Medicine, University of Augsburg, Stenglinstr. 2, 86156 Augsburg, Germany.

|July 5, 2024

Summary

New positron emission tomography (PET) tracers are advancing lymphoma imaging beyond standard [18F]Fluoro-deoxy-glucose PET scans. Immuno-PET shows promise for targeted immunotherapies, particularly in relapsed and refractory lymphoma cases.

Keywords:

CXCR4 Lymphoma Molecular imaging Oncologic imaging PET

More Related Videos

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Published on: February 3, 2023

Radiosynthesis, Quality Control, and Small Animal Positron Emission Tomography Imaging of 68Ga-Labelled Nano Molecules

Radiosynthesis, Quality Control, and Small Animal Positron Emission Tomography Imaging of ⁶⁸Ga-Labelled Nano Molecules

Published on: October 4, 2024

Related Experiment Videos

Last Updated: Jun 21, 2025

Murine Lymphocyte Labeling by 64Cu-Antibody Receptor Targeting for In Vivo Cell Trafficking by PET/CT

Murine Lymphocyte Labeling by 64Cu-Antibody Receptor Targeting for In Vivo Cell Trafficking by PET/CT

Published on: April 29, 2017

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Published on: February 3, 2023

Radiosynthesis, Quality Control, and Small Animal Positron Emission Tomography Imaging of 68Ga-Labelled Nano Molecules

Radiosynthesis, Quality Control, and Small Animal Positron Emission Tomography Imaging of ⁶⁸Ga-Labelled Nano Molecules

Published on: October 4, 2024

Area of Science:

Nuclear medicine and molecular imaging.
Oncology and hematology, specifically lymphoma research.
Development of novel diagnostic and therapeutic radiotracers.

Background:

Functional imaging with [18F]Fluoro-deoxy-glucose positron emission tomography (PET)/computed tomography is a standard in lymphoma diagnostics.
Limitations exist in current PET tracers for fully characterizing lymphoma biology and microenvironment.
Emerging radiotracers aim to target specific cellular and microenvironmental aspects of lymphoma.

Purpose of the Study:

To review novel PET tracers being developed for indolent and aggressive lymphoma subtypes.
To highlight the emerging role of immuno-PET in lymphoma imaging.
To summarize the current advancements and potential applications of immuno-PET in lymphoma, especially for relapsed/refractory disease.

Main Methods:

Review of current literature on novel PET tracers in lymphoma.
Analysis of the development and application of immuno-PET targeting lymphoma surface markers.
Synthesis of data on tracer performance across different lymphoma subtypes.

Main Results:

Development of novel PET tracers targeting lymphoma cell surface receptors, tumor biology, and microenvironment is ongoing.
Immuno-PET is emerging as a significant new imaging modality, particularly for guiding and monitoring immunotherapies.
These advancements hold particular promise for patients with relapsed and refractory lymphoma.

Conclusions:

Novel PET tracers offer expanded capabilities beyond [18F]Fluoro-deoxy-glucose PET for lymphoma characterization.
Immuno-PET represents a paradigm shift, linking molecular imaging with targeted immunotherapies.
Further research and clinical validation of these advanced PET tracers are crucial for optimizing lymphoma management.